125I放射性粒子治疗局部复发或转移乳腺癌的疗效观察  

Efficacy observation of 125I seed implantation therapy for locoregional recurrent and metastatic breast cancer

作　　者：义富翔 于滢华[1] 韦长元[1] 杨伟萍[2] 覃庆洪[1] 谭启杏 莫钦国[1] 黄真[1] 练斌[1] 

机构地区：[1]广西医科大学附属肿瘤医院乳腺外科,南宁530021 [2]广西医科大学附属肿瘤医院超声诊断科,南宁530021

出　　处：《中华肿瘤杂志》2016年第6期472-475,共4页Chinese Journal of Oncology

基　　金：广西科技厅攻关课题（桂科攻1355005-3-12）

摘　　要：目的观察125I放射性粒子植入治疗局部复发、转移性乳腺癌的临床疗效和不良反应，探讨其在乳腺癌综合治疗中的应用价值。方法对43例局部复发或转移的乳腺癌患者进行125I放射性粒子植入治疗，术后随访观察疗效和不良反应。结果43例患者均顺利完成125I放射性粒子植入治疗．病灶植入粒子3～32粒，平均13粒。43例患者的54个病灶中，完全缓解39个，部分缓解13个，疾病稳定2个，总有效率为96．3％。17例有局部疼痛的患者疼痛均缓解，疼痛缓解率为100％。术后随访14～60个月，中位随访36个月。全组患者的1、3、5年局部控制率分别为85．2％、53．7％和1．9％．1、3、5年生存率分别为95．3％、67．4％和37．2％。全组患者均未出现与植入放射性粒子相关的严重不良反应，仅有5例患者出现皮肤反应。结论125I放射性粒子治疗局部复发、转移乳腺癌疗效确切、创伤小、并发症少，可作为治疗局部复发、转移性乳腺癌的一种重要选择。Objective To assess the efficacy and side effects of 125I seed implantation for locoregional recurrent and metastatic breast cancer, and to discuss its role in the comprehensive therapy of breast cancer. Methods Forty-three patients with locoregional recurrent or metastatic breast cancer were included in this study. They received 125I seed implantation and were followed up to evaluate the efficacy and adverse reactions of the treatment. Results Among 54 lesions in the 43 cases, there were complete response （CR） in 39, partial response （PR） in 13, stable disease （SD） in 2 patients, with a response rate of 96.3%. All 17 cases with local pain achieved pain relief. With a median follow up of 36 months （range 14 to 60 months） ,the 1-, 3-, and 5-year local control rate was 85.2%, 53.7% and 1.9%, and the 1-, 3-, and 5- year survival rate was 95.3%, 67.4% and 37.2%, respectively. No serious radiotherapy side effect was observed. Conclusion In patients with unresectable locoregional recurrent or metastatic breast cancer, 125I seed implantation shows proved efficacy and few complications, and can be an important treatment option.

关 键 词：乳腺肿瘤 复发 肿瘤转移 125I粒子 近距离放射治疗 

分 类 号：R737.9[医药卫生—肿瘤]